Shield Therapeutics Price: STX Hits 12; Technical Indicators Suggest Potential Profit-Taking Phase

PUBLISHED: 22 Dec 2025 @ 07:54 | Comments (0) | More info about Azeez Mustapha

Shield Therapeutics Plc (LSE:STX) has reached the 12 price level, where short-term resistance may trigger profit-taking among investors. Technical indicators suggest momentum could pause or slightly retract unless renewed buying interest emerges, with monitoring of support zones critical for near-term trend continuation.

The stock-offering firm’s price touching 12 aligns with the short-term bullish trend indicated by the smaller EMA maintaining a position above the bigger EMA, suggesting persistent upward pressure. However, the Stochastic Oscillators have reached the overbought territory. It is important to monitor how the EMAs’ and Oscillators’ readings converge, because a clear break above resistance could strengthen the ongoing trend, while a reversal might indicate a short-term corrective pullback.

Resistance Levels: 13, 14, 15
Support Levels: 10, 9, 8

Can POS Sustain Consolidation If The 15-Day EMA Remains Positioned Closely Above The Candlesticks?

Shield Therapeutics Plc’s upward trend is supported by the smaller EMA staying above the bigger EMA, with Oscillators signaling strong buying momentum. However, overbought signals suggest cautious monitoring, as short-term corrective pullbacks could emerge before the trend resumes.

The 15-day EMA remains above the 50-day EMA, indicating that short-term bullish momentum is still intact, though the gap is narrowing. Meanwhile, the Stochastic Oscillators have entered the overbought region, signaling a potential slowdown or minor corrective pullback if selling pressure intensifies.

Learn from market wizards: Books to take your trading to the next

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

Follow @ItuGlobal

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.